MAGELLAN LONGEVITY
HomeResearchStudy library › C-reactive protein and other markers of inflammation in the…
Study summary · Cardiovascular & vascular aging

Can measuring markers of inflammation improve the prediction of cardiovascular event risk?

In one paragraph

hs-CRP Inflammation Test, a case-control study (N Engl J Med 2000, PMID 10733371) — in multivariate analyses, only hs-CRP (relative risk 1.5) and the ratio of total cholesterol to HDL cholesterol (relative risk 1.4) independently predicted risk. Adding C-reactive protein to standard lipid screening can better identify postmenopausal women at risk for cardiovascular events.

Source: N Engl J Med 2000, PMID 10733371 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

N Engl J Med · 2000 · PMID 10733371 · DOI 10.1056/NEJM200003233421202

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Adding C-reactive protein to standard lipid screening can better identify postmenopausal women at risk for cardiovascular events.

The question

Can measuring markers of inflammation improve the prediction of cardiovascular event risk?

What they tested

Measurement of markers of inflammation, in addition to traditional risk factors, will improve the prediction of cardiovascular event risk.

How they did it

A prospective, nested case-control study was conducted among 28,263 apparently healthy postmenopausal women over a mean follow-up of three years. Researchers assessed the risk of cardiovascular events associated with baseline levels of various markers, including high-sensitivity C-reactive protein (hs-CRP), serum amyloid A, interleukin-6, soluble intercellular adhesion molecule type 1 (sICAM-1), homocysteine, and lipid measurements. Cardiovascular events included death from coronary heart disease, nonfatal myocardial infarction or stroke, or the need for coronary-revascularization procedures.

What they found

Hs-CRP was the strongest univariate predictor of cardiovascular events, with a relative risk of 4.4 for women in the highest versus lowest quartile. Other significant univariate predictors included serum amyloid A (3.0), sICAM-1 (2.6), interleukin-6 (2.2), homocysteine (2.0), total cholesterol (2.4), LDL cholesterol (2.4), apolipoprotein B-100 (3.4), HDL cholesterol (0.3), and the ratio of total cholesterol to HDL cholesterol (3.4). Prediction models incorporating inflammation markers and lipids were significantly better than lipid-only models (P<0.001). Hs-CRP and serum amyloid A were significant predictors even in women with LDL cholesterol below 130 mg/dL. In multivariate analyses, only hs-CRP (relative risk 1.5) and the ratio of total cholesterol to HDL cholesterol (relative risk 1.4) independently predicted risk.

Univariate Relative Risk of Cardiovascular Events (Highest vs. Lowest Quartile)
Values shown: Relative Risk
hs-CRP4.4
Serum Amyloid A3
sICAM-12.6
Interleukin-62.2
Homocysteine2
Total Cholesterol2.4
LDL Cholesterol2.4
Apolipoprotein B-1003.4
HDL Cholesterol0.3
Total Chol/HDL Chol Ratio3.4

This chart shows the univariate relative risk of cardiovascular events for women in the highest quartile compared to the lowest quartile for various markers.

What it means

Adding C-reactive protein measurement to lipid-based screening may improve the identification of individuals at risk for cardiovascular events.

Limitations

The study was conducted in apparently healthy postmenopausal women, which may limit generalizability to other populations. The follow-up period was a mean of three years, which might not capture long-term risks.

“hs-CRP was the strongest univariate predictor of the risk of cardiovascular events”— from the published abstract, N Engl J Med 2000

The paper at a glance

TitleC-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
JournalN Engl J Med
Year2000
PMID10733371 ↗
DOI10.1056/NEJM200003233421202 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

hs-CRP Inflammation Test

Across large prospective cohorts and meta-analyses, higher hs-CRP is consistently associated with increased risk of coronary heart disease, stroke, cardiovascular and non-vascular mortality, and with aging-related states such as frailty and dementia;

hs-CRP Inflammation Test

High-sensitivity C-reactive protein (hs-CRP) is a blood test that measures very low concentrations of…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Can measuring markers of inflammation improve the prediction of cardiovascular event risk? [Plain-English summary of N Engl J Med 2000, PMID 10733371, DOI 10.1056/NEJM200003233421202]. Magellan Longevity. https://magellanlongevity.com/study/d10733371.html
BibTeX
@misc{magellan_d10733371, title = {Can measuring markers of inflammation improve the prediction of cardiovascular event risk?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d10733371.html}}, note = {Plain-English summary of PubMed PMID 10733371; DOI 10.1056/NEJM200003233421202; N Engl J Med 2000. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d10733371.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 10733371 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.